Browsing University of Hertfordshire by Author "Uchegbu, Ijeoma F."

Now showing items 1-6 of 6

    • Active Targeting 

      Serrano Lopez, Dolores Remedios; Lalatsa, Lalatsa (Springer Nature, 2013)

    • Amphiphilic poly(l-amino acids) : New materials for drug delivery 

      Lalatsa, Aikaterini; Schaetzlein, Andreas G.; Mazza, Mariarosa; Thi Bich Hang Le, [No Value]; Uchegbu, Ijeoma F. (2012-07-20)
      The formulation of drug compounds into medicines will increasingly rely on the use of specially tailored molecules, which fundamentally alter the drug's pharmacokinetics to enable its therapeutic activity. This is particularly ...

    • The effect of polymer architecture on the nano self-assemblies based on novel comb-shaped amphiphilic poly(allylamine) 

      Thompson, Colin J.; Ding, Caixia; Qu, Xiaozhong; Yang, Zhenzhong; Uchegbu, Ijeoma F.; Tetley, Laurence; Cheng, Woei Ping (2008-11)
      Twelve novel poly(allylamine) (PAA)-based, comb-shaped amphiphilic polymers have been developed. Hydrophobic groups of cetyl, palmitoyl and cholesteryl were randomly grafted to PAA and quaternisation was carried out on ...

    • Peptides, Proteins and Antibodies 

      Lalatsa, Lalatsa (Springer Nature, 2013)
      Peptide and protein therapeutics are increasingly able to address a growing range of clinical pathologies and their high specificity and potency combined with low toxicity of metabolic products and minimal potential for ...

    • Polymeric Nanoparticles 

      Uchegbu, I.F.; Lalatsa, Lalatsa; Wong, Dennis (Springer Nature, 2013)
      Self-assembling polymers, which are either amphiphilic block copolymers with hydrophobic and hydrophilic blocks, hydrophilic polymer backbones substituted with hydrophobic units or polymers with a low aqueous solubility, ...

    • A prodrug nanoparticle approach for the oral delivery of a hydrophilic peptide, leucine(5)-enkephalin, to the brain 

      Lalatsa, Aikaterini; Lee, Vivian; Malkinson, John P.; Zloh, Mire; Schätzlein, Andreas G; Uchegbu, Ijeoma F. (2012-06)
      The oral use of neuropeptides to treat brain disease is currently not possible because of a combination of poor oral absorption, short plasma half-lives and the blood-brain barrier. Here we demonstrate a strategy for ...